BR112023021867A2 - Composições de anticorpo anti-tslp e seus usos - Google Patents
Composições de anticorpo anti-tslp e seus usosInfo
- Publication number
- BR112023021867A2 BR112023021867A2 BR112023021867A BR112023021867A BR112023021867A2 BR 112023021867 A2 BR112023021867 A2 BR 112023021867A2 BR 112023021867 A BR112023021867 A BR 112023021867A BR 112023021867 A BR112023021867 A BR 112023021867A BR 112023021867 A2 BR112023021867 A2 BR 112023021867A2
- Authority
- BR
- Brazil
- Prior art keywords
- tslp antibody
- antibody compositions
- compositions
- tslp
- antibody
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Pulmonology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163178938P | 2021-04-23 | 2021-04-23 | |
| PCT/US2022/025994 WO2022226339A1 (en) | 2021-04-23 | 2022-04-22 | Anti-tslp antibody compositions and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023021867A2 true BR112023021867A2 (pt) | 2023-12-19 |
Family
ID=81597810
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023021867A BR112023021867A2 (pt) | 2021-04-23 | 2022-04-22 | Composições de anticorpo anti-tslp e seus usos |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20240190951A1 (https=) |
| EP (1) | EP4326766A1 (https=) |
| JP (1) | JP2024517418A (https=) |
| KR (1) | KR20240000537A (https=) |
| CN (1) | CN117203233A (https=) |
| AR (1) | AR125408A1 (https=) |
| AU (1) | AU2022262421A1 (https=) |
| BR (1) | BR112023021867A2 (https=) |
| CA (1) | CA3216655A1 (https=) |
| CL (1) | CL2023003155A1 (https=) |
| CO (1) | CO2023014181A2 (https=) |
| CR (1) | CR20230531A (https=) |
| IL (1) | IL307540A (https=) |
| JO (1) | JOP20230265A1 (https=) |
| MX (1) | MX2023012363A (https=) |
| PE (1) | PE20240068A1 (https=) |
| TW (1) | TW202308690A (https=) |
| UY (1) | UY39736A (https=) |
| WO (1) | WO2022226339A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12110324B2 (en) | 2022-07-22 | 2024-10-08 | Flagship Pioneering Innovations Vi, Llc | Antigen binding molecules targeting thymic stromal lymphopoietin (TSLP) |
| TW202448501A (zh) | 2023-02-02 | 2024-12-16 | 美商麥迪紐有限責任公司 | 用抗ｔｓｌｐ抗體治療慢性鼻竇炎 |
| IL324470A (en) | 2023-05-18 | 2026-01-01 | Medimmune Llc | Treatment of corticosteroid-dependent asthma using anti-TSLP antibody |
| WO2025147632A1 (en) | 2024-01-05 | 2025-07-10 | Medimmune, Llc | Treatment of chronic obstructive pulmonary disease with anti-tslp antibody |
| WO2025221247A1 (en) | 2024-04-17 | 2025-10-23 | Amgen Inc. | Treatment of eosinophilic esophagitis with anti-tslp antibody |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
| US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
| GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
| US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
| ATE135397T1 (de) | 1988-09-23 | 1996-03-15 | Cetus Oncology Corp | Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| ATE158021T1 (de) | 1990-08-29 | 1997-09-15 | Genpharm Int | Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper |
| US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
| US7982016B2 (en) | 2007-09-10 | 2011-07-19 | Amgen Inc. | Antigen binding proteins capable of binding thymic stromal lymphopoietin |
| US8359965B2 (en) | 2007-09-17 | 2013-01-29 | Oxford J Craig | Apparatus and method for broad spectrum radiation attenuation |
| CN102281901A (zh) * | 2008-11-20 | 2011-12-14 | 弗·哈夫曼-拉罗切有限公司 | 治疗性蛋白质制剂 |
| WO2012007495A1 (en) | 2010-07-15 | 2012-01-19 | F. Hoffmann-La Roche Ag | Antibodies specifically binding to human tslpr and methods of use |
| AT510032B1 (de) | 2010-11-30 | 2012-01-15 | Steiner Erwin Ing | Montageeinrichtung für fassadenelemente |
| TWI593705B (zh) * | 2011-12-28 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | Humanized anti-epiregulin antibody and cancer therapeutic agent containing the antibody as an active ingredient |
| US9100245B1 (en) | 2012-02-08 | 2015-08-04 | Amazon Technologies, Inc. | Identifying protected media files |
| WO2014031718A1 (en) * | 2012-08-23 | 2014-02-27 | Merck Sharp & Dohme Corp. | Stable formulations of antibodies to tslp |
| US9306926B2 (en) | 2013-03-15 | 2016-04-05 | Brian A. Truong | User authentication using unique hidden identifiers |
| WO2015116315A1 (en) | 2014-01-29 | 2015-08-06 | Amgen Inc. | Overexpression of n-glycosylation pathway regulators to modulate glycosylation of recombinant proteins |
| FI3218005T3 (fi) * | 2014-11-12 | 2023-03-31 | Seagen Inc | Glykaanin kanssa vuorovaikutteisia yhdisteitä ja käyttömenetelmiä |
| KR20170123315A (ko) * | 2015-03-11 | 2017-11-07 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | Tslp 결합 단백질 |
| KR102666879B1 (ko) * | 2017-04-12 | 2024-05-23 | 암젠 인크 | 항-tslp 항체를 이용한 천식의 치료 |
| JP7200134B2 (ja) | 2017-06-08 | 2023-01-06 | アムジエン・インコーポレーテツド | トルク駆動式薬物送達デバイス |
| ES2978396T3 (es) * | 2017-08-01 | 2024-09-11 | Amgen Inc | Sistemas y métodos para la preparación en tiempo real de una muestra de polipéptidos para el análisis por espectrometría de masas |
| MA50557A (fr) | 2017-11-10 | 2020-09-16 | Amgen Inc | Pistons pour dispositifs d'administration de médicament |
| EP4321870B1 (en) | 2018-03-13 | 2025-07-30 | Amgen Inc. | Methods for the preparation of trypsin-resistant polypeptides for mass spectrometric analysis |
| TW202541859A (zh) | 2018-10-15 | 2025-11-01 | 美商安進公司 | 具有阻尼機構之藥物遞送裝置及自動注射器 |
| WO2020081480A1 (en) | 2018-10-15 | 2020-04-23 | Amgen Inc. | Platform assembly process for drug delivery device |
| JP7562563B2 (ja) | 2019-04-30 | 2024-10-07 | アムジエン・インコーポレーテツド | バイオ医薬品生産における細胞株選択のためのデータ駆動予測モデリング |
| AU2020288652A1 (en) | 2019-06-05 | 2021-11-18 | Amgen Inc. | Methods of identifying attributes of therapeutic proteins |
-
2022
- 2022-04-22 EP EP22722640.4A patent/EP4326766A1/en active Pending
- 2022-04-22 US US18/287,593 patent/US20240190951A1/en active Pending
- 2022-04-22 AR ARP220101047A patent/AR125408A1/es unknown
- 2022-04-22 BR BR112023021867A patent/BR112023021867A2/pt unknown
- 2022-04-22 CN CN202280029246.4A patent/CN117203233A/zh active Pending
- 2022-04-22 MX MX2023012363A patent/MX2023012363A/es unknown
- 2022-04-22 CA CA3216655A patent/CA3216655A1/en active Pending
- 2022-04-22 JP JP2023564144A patent/JP2024517418A/ja active Pending
- 2022-04-22 PE PE2023002912A patent/PE20240068A1/es unknown
- 2022-04-22 CR CR20230531A patent/CR20230531A/es unknown
- 2022-04-22 AU AU2022262421A patent/AU2022262421A1/en active Pending
- 2022-04-22 TW TW111115482A patent/TW202308690A/zh unknown
- 2022-04-22 WO PCT/US2022/025994 patent/WO2022226339A1/en not_active Ceased
- 2022-04-22 KR KR1020237039567A patent/KR20240000537A/ko active Pending
- 2022-04-22 IL IL307540A patent/IL307540A/en unknown
- 2022-04-27 UY UY0001039736A patent/UY39736A/es unknown
-
2023
- 2023-10-22 JO JOJO/P/2023/0265A patent/JOP20230265A1/ar unknown
- 2023-10-23 CL CL2023003155A patent/CL2023003155A1/es unknown
- 2023-10-24 CO CONC2023/0014181A patent/CO2023014181A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW202308690A (zh) | 2023-03-01 |
| JP2024517418A (ja) | 2024-04-22 |
| JOP20230265A1 (ar) | 2023-10-22 |
| KR20240000537A (ko) | 2024-01-02 |
| PE20240068A1 (es) | 2024-01-11 |
| CR20230531A (es) | 2024-01-08 |
| AR125408A1 (es) | 2023-07-12 |
| MX2023012363A (es) | 2023-11-01 |
| CO2023014181A2 (es) | 2023-10-30 |
| EP4326766A1 (en) | 2024-02-28 |
| CL2023003155A1 (es) | 2024-04-19 |
| CN117203233A (zh) | 2023-12-08 |
| WO2022226339A9 (en) | 2023-08-24 |
| CA3216655A1 (en) | 2022-10-27 |
| UY39736A (es) | 2022-10-31 |
| WO2022226339A1 (en) | 2022-10-27 |
| US20240190951A1 (en) | 2024-06-13 |
| IL307540A (en) | 2023-12-01 |
| AU2022262421A1 (en) | 2023-10-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112023021867A2 (pt) | Composições de anticorpo anti-tslp e seus usos | |
| CL2024003552A1 (es) | Anticuerpo anti-ccr8; método de producción; composición farmacéutica; y su uso. | |
| MX2021006681A (es) | Anticuerpos anti-claudina y usos de los mismos. | |
| MX2021013581A (es) | Composiciones de nanoemulsiones que comprenden ingredientes biologicamente activos. | |
| CO2020010303A2 (es) | Conjugados de il-15, y sus usos | |
| MX2020013421A (es) | Composiciones de dióxido de silicio de carbono poroso biogénico, métodos de elaboracion y uso de estas. | |
| MY207121A (en) | Anti-ror antibody constructs | |
| CL2020001762A1 (es) | Formas cristalinas del derivado de 4-pirimidinsulfamida de aprocitentán. (divisional solicitud 201902464) | |
| ECSP20034868A (es) | Conjugados anticuerpo anti-cd40-fármaco | |
| BR112023022041A2 (pt) | Anticorpos anti-tslp modificados | |
| BR112018017172A2 (pt) | anticorpos monoclonais anti-alfa-sinucleína para prevenção da agregação de tau | |
| JOP20190189A1 (ar) | تركيبة صيدلانية ذات درجة حموضة منخفضة تتضمن بنيات جسم مضاد يستهدف الخلية t | |
| BR112023024837A2 (pt) | Anticorpos anti-ccr8 | |
| BR112018067525A2 (pt) | anticorpos tendo especificidade para o btla e seus usos | |
| BR112015032736A2 (pt) | inibidores de bromodomínio cristalino | |
| BR112023020450A2 (pt) | Anticorpos anti-cd19 e estruturas car-t | |
| MX2017011007A (es) | Composicion para uso para mejorar la consistencia o la frecuencia de las heces en infantes o niños pequeños. | |
| CL2024000305A1 (es) | Composiciones y métodos para la degradación selectiva de proteínas diseñadas por ingeniería | |
| PY2018313A (es) | Composición farmacéutica acuosa de anticuerpo anti-il17a y su uso | |
| BR112023008490A2 (pt) | Variantes de anticorpo bovino | |
| CO2020004407A2 (es) | Formulaciones de espora de nutriente y usos de las mismas | |
| MX2020011986A (es) | Composiciones que comprenden glucosa y hemicelulosa y su uso. | |
| BR112022024382A2 (pt) | Formas sólidas de pralsetinibe | |
| CL2024002648A1 (es) | Composiciones que comprenden aticaprant. | |
| ECSP22097927A (es) | Composición acuosa de un fungicida de ditiocarbamato |